Among hematological malignancies, antibody blockade of the PD-1/PD-L1 pathway is a highly effective therapeutic approach for patients with classical Hodgkin lymphoma, 97% of which typically exhibits an overexpression of PD-L1 due to the alteration in chromosome 9p24.1 (54). This evidence concerns the gene CD274 and Hodgkins lymphoma.